The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a study found. In 38 immunocompromised persons who received either the ...

While issuing its RSV warning mandate on Tuesday, the FDA added that the benefits of vaccination with Abrysvo and Arexvy “continue to outweigh their risks.” During an FDA advisory panel ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...